Comparison of the value of the STOP-BANG questionnaire with oxygen desaturation index in screening obstructive sleep apnea in Germany
Sleep and Breathing · 2023-08 · 27 (4) · 1315-1323
DOI: 10.1007/s11325-022-02727-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sleep and Breathing, online erschienen am 21.10.2022. Verfasst von Yan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Sleep Medicine Center, Charité-Universitätsmedizin Berlin, Luisenstrasse 13, 10117, Berlin, Germany. yan.wang@charite.de. Hauptthemen laut MEDLINE: Oxygen, Sleep Apnea, Obstructive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
Purpose
Despite polysomnography being the gold standard method of diagnosing obstructive sleep apnea (OSA), it is time-consuming and has long waiting lists. Alternative methods including questionnaires and portable sleep devices have been developed to increase the speed of diagnosis. However, most questionnaires such as the STOP-BANG questionnaire (SBQ) are limited due to low specificity. This study evaluated the value of SBQ to screen for OSA and compared it with the oxygen desaturation index (ODI) and their combination.
Methods
This retrospective study included patients who completed the SBQ and underwent a night at the sleep lab or home sleep testing. The ODI was extracted from these sleep study reports. The combination of SBQ with ODI and their individual scores were compared with apnea–hypopnea index (AHI) in terms of their accuracy in diagnosing OSA. Sensitivity, specificity, and area under the curve (AUC) for different severities of OSA were calculated and compared.
Results
Among 132 patients, SBQ showed a sensitivity of 0.9 and a specificity of 0.3 to screen for OSA. As the severity of OSA increased, the sensitivity increased whilst specificity decreased for both measurements. ODI achieved an increased specificity of 0.8 and could correctly diagnose OSA 86% of the time which was better than SBQ’s 60%. For all severities of OSA, ODI alone displayed a larger AUC than SBQ and similar AUC to their combination.
Conclusion
ODI produced a higher specificity and AUC than SBQ. Furthermore, ODI combined with SBQ failed to increase diagnostic value. Therefore, ODI may be the preferred way to initially screen patients for OSA as an easy-to-use alternative compared to SBQ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Sleep Medicine Center, Charité-Universitätsmedizin Berlin, Luisenstrasse 13, 10117, Berlin, Germany. yan.wang@charite.de.
- Interdisciplinary Sleep Medicine Center, Charité-Universitätsmedizin Berlin, Luisenstrasse 13, 10117, Berlin, Germany.
- The Federal State Autonomous Educational Institution of Higher Education, I.M Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia.
ORCID-Profile: Yan Wang, Thomas Penzel
Förderung
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Wang, Y., Fietze, I., Salanitro, M., & Penzel, T. (2023). Comparison of the value of the STOP-BANG questionnaire with oxygen desaturation index in screening obstructive sleep apnea in Germany. Sleep and Breathing, 27(4), 1315-1323. https://doi.org/10.1007/s11325-022-02727-7
Vancouver
Wang Y, Fietze I, Salanitro M, Penzel T. Comparison of the value of the STOP-BANG questionnaire with oxygen desaturation index in screening obstructive sleep apnea in Germany. Sleep and Breathing. 2023;27(4):1315-1323. doi:10.1007/s11325-022-02727-7
BibTeX
@article{Wang2023,
author = {Wang, Yan and Fietze, Ingo and Salanitro, Matthew and Penzel, Thomas},
title = {Comparison of the value of the STOP-BANG questionnaire with oxygen desaturation index in screening obstructive sleep apnea in Germany},
journal = {Sleep and Breathing},
year = {2023},
volume = {27},
number = {4},
pages = {1315--1323},
doi = {10.1007/s11325-022-02727-7}
}
EUVIMED